This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Mirati Therapeutics Salute del bilancio
Salute finanziaria criteri di controllo 5/6
Mirati Therapeutics has a total shareholder equity of $946.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.1B and $183.2M respectively.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
US$0
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$978.52m |
| Patrimonio netto | US$946.47m |
| Totale passività | US$183.24m |
| Totale attività | US$1.13b |
Aggiornamenti recenti sulla salute finanziaria
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21Analisi della posizione finanziaria
Passività a breve termine: MRTX's short term assets ($1.0B) exceed its short term liabilities ($137.4M).
Passività a lungo termine: MRTX's short term assets ($1.0B) exceed its long term liabilities ($45.9M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: MRTX is debt free.
Riduzione del debito: MRTX has not had any debt for past 5 years.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: MRTX has sufficient cash runway for more than a year based on its current free cash flow.
Previsione Cash Runway: Insufficient data to determine if MRTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.